Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.71
+2.91 (11.73%)
Apr 29, 2026, 3:20 PM EDT - Market open
Agios Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | - | 89.13 | 76.25 | 88.21 | 139.26 | 203.13 | Upgrade
|
| Short-Term Investments | - | 765.3 | 817.46 | 688.72 | 643.86 | 816.89 | Upgrade
|
| Cash & Short-Term Investments | 854.43 | 854.43 | 893.71 | 776.93 | 783.12 | 1,020 | Upgrade
|
| Cash Growth | -4.36% | -4.40% | 15.03% | -0.79% | -23.23% | 78.04% | Upgrade
|
| Accounts Receivable | - | 10.58 | 4.11 | 2.81 | 2.21 | - | Upgrade
|
| Other Receivables | - | 0.2 | - | 1.1 | 0.3 | 7.28 | Upgrade
|
| Receivables | - | 10.78 | 4.11 | 3.91 | 2.51 | 7.28 | Upgrade
|
| Inventory | - | 32.92 | 27.62 | 19.08 | 8.49 | - | Upgrade
|
| Prepaid Expenses | - | 43.93 | 40.17 | 33.92 | 38.66 | 36.94 | Upgrade
|
| Total Current Assets | - | 942.05 | 965.6 | 833.84 | 832.77 | 1,064 | Upgrade
|
| Property, Plant & Equipment | - | 41.23 | 54.55 | 69.79 | 88.12 | 104.23 | Upgrade
|
| Long-Term Investments | - | 310.01 | 638.32 | 29.44 | 313.87 | 266.38 | Upgrade
|
| Other Long-Term Assets | - | 3.93 | 4.72 | 4.06 | 3.96 | 2.9 | Upgrade
|
| Total Assets | - | 1,297 | 1,663 | 937.12 | 1,239 | 1,438 | Upgrade
|
| Accounts Payable | - | 18.36 | 16.64 | 9.78 | 18.62 | 16.7 | Upgrade
|
| Accrued Expenses | - | 45.46 | 46.86 | 43.17 | 30.35 | 31.97 | Upgrade
|
| Current Portion of Leases | - | 18.39 | 16.78 | 15.01 | 13.66 | 11.16 | Upgrade
|
| Current Income Taxes Payable | - | - | 0.87 | - | - | - | Upgrade
|
| Total Current Liabilities | - | 82.21 | 81.16 | 67.96 | 62.63 | 59.83 | Upgrade
|
| Long-Term Leases | - | 21.82 | 40.21 | 56.99 | 72 | 85.94 | Upgrade
|
| Other Long-Term Liabilities | - | 0.09 | 0.88 | 1.16 | 3.28 | - | Upgrade
|
| Total Liabilities | - | 104.11 | 122.24 | 126.1 | 137.9 | 145.76 | Upgrade
|
| Common Stock | - | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | Upgrade
|
| Additional Paid-In Capital | - | 2,555 | 2,494 | 2,437 | 2,386 | 2,334 | Upgrade
|
| Retained Earnings | - | -561.71 | -148.92 | -822.65 | -470.56 | -238.76 | Upgrade
|
| Treasury Stock | - | -802.49 | -802.49 | -802.49 | -802.49 | -802.49 | Upgrade
|
| Comprehensive Income & Other | - | 2.19 | -1.52 | -0.44 | -12.54 | -1.2 | Upgrade
|
| Shareholders' Equity | 1,193 | 1,193 | 1,541 | 811.02 | 1,101 | 1,292 | Upgrade
|
| Total Liabilities & Equity | - | 1,297 | 1,663 | 937.12 | 1,239 | 1,438 | Upgrade
|
| Total Debt | 40.21 | 40.21 | 56.99 | 72 | 85.66 | 97.09 | Upgrade
|
| Net Cash (Debt) | 1,124 | 1,124 | 1,475 | 734.37 | 1,011 | 1,189 | Upgrade
|
| Net Cash Growth | -18.04% | -23.78% | 100.86% | -27.39% | -14.96% | 110.37% | Upgrade
|
| Net Cash Per Share | 19.28 | 19.39 | 25.48 | 13.20 | 18.46 | 19.67 | Upgrade
|
| Filing Date Shares Outstanding | 58.78 | 58.59 | 57.3 | 56.19 | 55.29 | 54.64 | Upgrade
|
| Total Common Shares Outstanding | 58.78 | 58.45 | 57.16 | 55.95 | 55.04 | 54.33 | Upgrade
|
| Working Capital | - | 859.85 | 884.44 | 765.88 | 770.14 | 1,004 | Upgrade
|
| Book Value Per Share | 20.41 | 20.41 | 26.96 | 14.50 | 20.00 | 23.78 | Upgrade
|
| Tangible Book Value | 1,193 | 1,193 | 1,541 | 811.02 | 1,101 | 1,292 | Upgrade
|
| Tangible Book Value Per Share | 20.41 | 20.41 | 26.96 | 14.50 | 20.00 | 23.78 | Upgrade
|
| Machinery | - | 30.62 | 29.76 | 29.73 | 35.12 | 33.8 | Upgrade
|
| Construction In Progress | - | 2.75 | 0.9 | 0.61 | 0.66 | 7.37 | Upgrade
|
| Leasehold Improvements | - | 37.52 | 37.52 | 37.28 | 37.28 | 32.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.